CHADS Score Calculator (Original)

About

The CHADS score (Congestive heart failure, Hypertension, Age ≥75, Diabetes, prior Stroke/TIA) was developed by Gage et al. and published in JAMA in 2001 as the first widely adopted clinical risk stratification tool for predicting stroke in patients with non-valvular atrial fibrillation. The derivation cohort consisted of 1,733 Medicare beneficiaries aged 65-95 with non-rheumatic AF, and the score was validated in a separate cohort of 1,827 patients from the National Registry of Atrial Fibrillation. Each risk factor contributes 1 point, except prior stroke or TIA which carries a weight of 2 points given its strong independent association with recurrent cerebrovascular events, yielding a total score ranging from 0 to 6. The score demonstrated a c-statistic of 0.82 in the validation cohort, indicating excellent predictive discrimination. However, a key limitation emerged over time: approximately 85% of AF patients fell into the intermediate-risk CHADS categories (score 1-2), where the score failed to adequately discriminate between patients who would benefit from anticoagulation versus those who would not. This limitation prompted the development of the more refined CHADS-VASc score in 2010. Despite being largely superseded by its successor, the CHADS score retains historical importance and remains a useful rapid bedside tool for initial risk estimation, particularly when detailed risk factor assessment is not immediately feasible. Its evidence level is Grade B, supported by multiple validation studies across various populations.

Formula

CHF (1) + Hypertension (1) + Age ≥75 (1) + Diabetes (1) + Stroke/TIA (2)

The CHADS score uses five clinical variables, each independently associated with stroke risk in atrial fibrillation. Congestive heart failure (recent decompensation or documented left ventricular dysfunction) contributes 1 point. Hypertension (resting blood pressure >140/90 mmHg or current antihypertensive pharmacotherapy) contributes 1 point. Age ≥75 years contributes 1 point, reflecting the increased cerebrovascular risk associated with advanced age. Diabetes mellitus (fasting plasma glucose ≥126 mg/dL or ongoing antidiabetic treatment) contributes 1 point. Prior stroke, transient ischemic attack, or systemic thromboembolism is the most heavily weighted variable at 2 points, based on the observation that a history of cerebrovascular disease increases the risk of recurrent events by approximately 2.5-fold compared to patients without such history. The total score ranges from 0 to 6, with higher scores indicating progressively greater annual stroke risk: a score of 0 corresponds to an annual stroke risk of approximately 1.9% without antithrombotic therapy, while a score of 6 corresponds to an annual stroke risk exceeding 18%. Patients are stratified into three risk categories: low (score 0, annual stroke risk 1.9%), moderate (score 1-2, annual stroke risk 2.8-4.0%), and high (score 3-6, annual stroke risk 5.9-18.2%). The score assumes a linear relationship between increasing points and escalating stroke risk, though this assumption is less accurate at the lower end of the scale where CHADS-VASc provides superior discrimination.

Score Interpretation

The CHADS score marked a paradigm shift in atrial fibrillation management by introducing an evidence-based, systematic approach to stroke risk stratification at a time when anticoagulation decisions were largely based on unstructured clinical judgment. Its publication in 2001 led to a significant increase in appropriate anticoagulation prescribing for high-risk patients and a corresponding reduction in inappropriate warfarin use in low-risk patients. The score was incorporated into early versions of the ACC/AHA and ESC guidelines and remains referenced in historical contexts and quality improvement initiatives. However, current guidelines from the AHA/ACC (2024), ESC (2020), and NICE (2021) universally recommend the CHADS-VASc score as the preferred risk stratification tool due to its superior ability to identify truly low-risk patients. The CHADS score's principal limitation is its classification of most AF patients (approximately 85%) as intermediate risk (score 1-2), providing limited actionable discrimination. A prospective study comparing the two scores found that CHADS-VASc reclassified 21% of patients deemed intermediate risk by CHADS into either low-risk (no anticoagulation needed) or high-risk (anticoagulation clearly indicated) categories. Despite these limitations, the CHADS score maintains clinical utility as a rapid bedside screening tool, particularly in resource-limited settings where full CHADS-VASc variable ascertainment may not be possible. It also serves as an important educational tool for trainees to understand the fundamental risk factors for cardioembolic stroke in AF.

Reference Ranges